Lung cancer accounts for 14% of all diagnosed cancers in Canada from which 80% will be tested for programmed cell death protein 1 (PD-L1) through the course of the disease. This project aims to develop PD-L1 Mass Spectrometry (MS)-based assays for use in immune-oncology. The Receptor, MRM Proteomics, in partnership with the academic leaders, will develop two alternative analytical pipelines based on multiple reaction monitoring (MRM, for research purposes) and immuno MALDI (iMALDI technology, suitable for clinical diagnostics). The anticipated revenues for MRMP’s new PD-L1 kit is projected as $3.5 million over the first 5 years plus the addition of the iMALDI technology to 20% of PD-L1 testing would generate more than $250 million.
Lead Genome Centre: Génome Québec
Co-project leaders:
| Alan | Spatz | Lady Davis Institute, Jewish General Hospital |
| Claude | Leduc | MRM Proteomics |